Diamond Ranch Foods (PLPL) 0.4100 $PLPL
Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health
Marketwired - Wed Oct 29, 8:08AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaà and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University" in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaà to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University.
Plandai Biotechnology's Technology Could Prove Potent in Battling Alzheimers Disease
Marketwired - Tue Oct 21, 8:10AM CDT
In the recently released preliminary results from Plandaà Biotechnology's (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare(TM) Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.
Plandai Biotechnology Marketing of First Product to Customers Should Be a Cinch With Proven Higher Bioavailability
Marketwired - Fri Oct 17, 8:02AM CDT
Plandaà Biotechnology (OTCQB: PLPL) began to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014. The company announced that it will first ship samples of its Phytofare(TM) Catechin Complex, to a list of potential customers worldwide. PlandaÃ's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).
Plandai Biotechnology, Inc. Announces Update on Factory and Expected Plan to Market First Phytofare(TM) Product
Marketwired - Wed Oct 15, 8:28AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company" , a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the final equipment optimization is nearing completion at the Company's production facility in South Africa. Once the factory is officially "on-line" and its opening is announced, shipments of the Company's first Phytofare(TM) product to potential customers should begin before the end of the year.
Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
Plandai Biotechnology Gains Competitive Advantage With Preliminary Clinical Trial Results
Marketwire - Mon Sep 15, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) expects to begin commercial production of its green tea extract, Phytofare(TM) Catechin Complex, in the coming weeks when the first green tea crop of the season is ready for processing at the company's 8,000 acre Senteeko facility in South Africa. After receiving positive preliminary results from a human clinical trial that showed Plandai's product offers ten times more bioavailability than the commercially available extract it was compared to, the company could gain a competitive advantage over other less potent extracts.
Plandai Biotechnology's Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial Conducted in South Africa
Marketwire - Wed Sep 10, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company's green tea extract, Phytofare(TM) Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandai's Phytofare(TM) extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
Plandaí Biotechnology, Inc. Announces Preliminary Results of Study Showing Phytofaretm Catechin Complex Having Ten Times The Greater Bioavailability Than Generic Green Tea Extracts
ACCESSWIRE - Thu Sep 04, 8:11AM CDT
Greater Bioavailability Allows the Body to Experience More of the Positive Health Benefits of the Green Tea
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health
Marketwired - Wed Oct 29, 8:08AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaà and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University" in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaà to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University. Plandai Biotechnology's Technology Could Prove Potent in Battling Alzheimers Disease
Marketwired - Tue Oct 21, 8:10AM CDT
In the recently released preliminary results from Plandaà Biotechnology's (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare(TM) Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.
Plandai Biotechnology Marketing of First Product to Customers Should Be a Cinch With Proven Higher Bioavailability
Marketwired - Fri Oct 17, 8:02AM CDT
Plandaà Biotechnology (OTCQB: PLPL) began to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014. The company announced that it will first ship samples of its Phytofare(TM) Catechin Complex, to a list of potential customers worldwide. PlandaÃ's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).
Plandai Biotechnology, Inc. Announces Update on Factory and Expected Plan to Market First Phytofare(TM) Product
Marketwired - Wed Oct 15, 8:28AM CDT
Plandaà Biotechnology, Inc. (OTCQB: PLPL) ("PlandaÃ" or "the Company"
, a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the final equipment optimization is nearing completion at the Company's production facility in South Africa. Once the factory is officially "on-line" and its opening is announced, shipments of the Company's first Phytofare(TM) product to potential customers should begin before the end of the year. Plandai Biotechnology Expects Pfizer Viagra Patent Ruling Will Aid in Developing All-Natural Substitute to Treat Erectile Dysfunction
Marketwire - Mon Sep 29, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) has already begun cultivating and cloning the epimedium plants it recently acquired as part of its preliminary plans to develop and test what it anticipates will be an all-natural substitute for the widely popular erectile dysfunction (ED) drugs Viagra(R), Cialis(R) and Levitra(R).
Plandai Biotechnology Plans to Develop Extract to Enter Lucrative Erectile Dysfunction Market With All-Natural Substitute for Viagra(R)
Marketwire - Mon Sep 22, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently announced its preliminary plans to develop and test an all-natural Phytofare(TM) extract for erectile dysfunction (ED). With an ED market that brings in billions annually, it's not hard to figure out why Plandai would use its unique and proprietary extraction process to try to develop and test another possible extract -- this time providing an all-natural alternative to existing ED drugs like Viagra(R) and Cialis(R).
Plandai Biotechnology, Inc. to Develop All-Natural Phytofare(TM) Extract for Erectile Dysfunction
Marketwire - Wed Sep 17, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the acquisition of a strain of epimedium with high levels of icariin, the primary active compound in herbal epimedium, to develop an all-natural Phytofare(TM) extract for erectile dysfunction for further testing with the expectation that the extract could be sold as an active ingredient to pharmaceutical and nutraceutical manufacturers.
Plandai Biotechnology Gains Competitive Advantage With Preliminary Clinical Trial Results
Marketwire - Mon Sep 15, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) expects to begin commercial production of its green tea extract, Phytofare(TM) Catechin Complex, in the coming weeks when the first green tea crop of the season is ready for processing at the company's 8,000 acre Senteeko facility in South Africa. After receiving positive preliminary results from a human clinical trial that showed Plandai's product offers ten times more bioavailability than the commercially available extract it was compared to, the company could gain a competitive advantage over other less potent extracts.
Plandai Biotechnology's Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial Conducted in South Africa
Marketwire - Wed Sep 10, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company's green tea extract, Phytofare(TM) Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandai's Phytofare(TM) extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
Plandaí Biotechnology, Inc. Announces Preliminary Results of Study Showing Phytofaretm Catechin Complex Having Ten Times The Greater Bioavailability Than Generic Green Tea Extracts
ACCESSWIRE - Thu Sep 04, 8:11AM CDT
Greater Bioavailability Allows the Body to Experience More of the Positive Health Benefits of the Green Tea
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
